There was no medicine to control her plaque psoriasis, Jennifer Brown's face, scalp, body and neck were periodically covered with red, flaking patches so painful that they cracked and bleed.
She received relief from drugs, but they were expensive. For a while she was on Humira, made by AbbVie, with an average retail price of about $ 8,600 for two monthly injections. When the medication stopped working with her, Brown's doctor switched her to another drug. Today she is using another injection, Skyrizi, also by AbbVie, which costs about $ 36,000 for two quarterly injections – almost 40% more per year than Humira.
The pharmaceutical company provided a support program to help consumers like Brown pay their share, and that helped her pay co-payments. However, she faces the possibility of higher federal drug costs being finalized by the Trump administration this spring.
This rule, an annual directive that sets health plan standards for 2021, allows employers and insurance companies not to apply co-payment assistance of pharmaceutical companies to enrollees and up to out-of-pocket deductibles for any drug. That means that only payments made by the patient themselves will be involved in the calculations to achieve those spending goals and may put individuals responsible for thousands of dollars in expenses. medicine.
Advocates of consumers with chronic conditions say this rule will lead patients to diseases such as cancer and multiple sclerosis based on …